Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF)

Disseminated on behalf of Redwood AI Corp., may include paid advertisements.

Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) develops artificial intelligence-powered platforms focused on accelerating chemistry research and development across pharmaceutical, defense, public safety, and industrial applications. The company is working at the intersection of AI and chemistry, building tools intended to help organizations navigate increasingly complex scientific and development challenges. Redwood AI’s platforms are built on proprietary AI models and analytical infrastructure that improve as datasets and platform usage expand.

Redwood AI is positioning its technology across several emerging areas, including drug discovery, chemical development, and public safety applications tied to hazardous material analysis and chemical intelligence initiatives. Through collaborations involving academic institutions, government-supported programs, and commercial organizations, the company is advancing the use of AI-driven chemistry tools in both commercial and public-sector environments.

The company’s head office is located in Vancouver, British Columbia.

Public Safety and Defense Applications

Redwood AI is expanding its platform into hazardous material analysis, public safety, and defense-related applications. In April 2026, the company announced a collaboration with Aidos Innovations involving the development of an AI-supported analytical platform intended to assist toxic opioid detection and monitoring initiatives involving the Royal Canadian Mounted Police (RCMP), the Victoria Police Department, the Canada Border Services Agency, and public safety stakeholders through a British Columbia government-supported Track & Trace initiative.

The company is also advancing its Q-SAFE hazardous chemical risk classification initiative with support from the National Research Council of Canada Industrial Research Assistance Program. Redwood AI believes these initiatives demonstrate the platform’s applicability across chemical intelligence, safety monitoring, and defense-related environments.

Reactosphere

Reactosphere is Redwood AI’s proprietary AI platform designed to help organizations navigate complex chemical development workflows across pharmaceutical, industrial, public safety, and defense-related environments. By combining proprietary AI models with chemistry-focused data analysis tools, the platform is intended to support faster decision-making, improve experimental planning, and help research teams evaluate chemical pathways more efficiently.

The platform is designed to predict and optimize chemical synthesis pathways while incorporating sourcing intelligence, safety analysis, and manufacturing considerations into the evaluation process. Redwood AI states that Reactosphere’s models are trained on more than 1 billion molecules and more than 5 million chemical reactions, with expanded datasets under development through research collaborations intended to improve predictive capabilities further.

In May 2026, Redwood AI announced preliminary results from a research collaboration with the University of British Columbia aimed at expanding Reactosphere’s predictive capabilities. According to the company, the initiative increased the platform’s evaluated chemical reaction universe from approximately 4 million training examples to more than 21 million examples, supporting efforts to improve synthesis planning, route analysis, and broader chemical prediction capabilities over time.

Drug Discovery and Development

Redwood AI is positioning its platform to support AI-assisted small-molecule drug discovery and development workflows. In May 2026, the company announced a collaboration with Resilience Biosciences Inc. focused on applying Redwood’s computational chemistry, retrosynthetic analysis, and molecular design capabilities to therapeutic development programs.

The company believes its platform can help research teams evaluate chemical space more efficiently while supporting synthesis planning, candidate assessment, and early-stage development analysis. Redwood AI is also advancing platform capabilities intended to support future AI-enabled drug candidate generation initiatives.

Market Opportunity

Redwood AI is positioned across several large and expanding markets tied to defense applications, pharmaceutical development, chemical manufacturing infrastructure, and AI-assisted drug discovery. The company is targeting defense and chemical intelligence applications within the global defense spending market, which Spherical Insights estimates at approximately $2.7 trillion in 2024 and projects will reach approximately $6.38 trillion by 2035. According to Grand View Research, the global pharmaceutical market was estimated at approximately $1.74 trillion in 2025 and is projected to exceed $2.78 trillion by 2033, while the pharmaceutical CDMO market is projected to grow from approximately $197.4 billion in 2025 to approximately $392.67 billion by 2035.

Redwood AI also references the AI-enabled drug discovery market, estimated at approximately $6.93 billion in 2025 and projected to reach approximately $17.81 billion by 2035.

The company believes increasing investment in AI, advanced analytics, hazardous material detection, and security technologies is expanding demand for chemistry-focused AI platforms across government, industrial, and defense-related environments.

Leadership Team

Louis Dron, Chief Executive Officer, is a healthcare executive with experience spanning clinical science, diagnostics, health technology, and research leadership. His background includes work in hospital systems and clinical diagnostics in the United Kingdom, along with leadership roles focused on integrating real-world evidence, epidemiology, and biostatistics into healthcare decision-making. Dron has also served as an advisor to the Canadian Drug Agency and the Bill & Melinda Gates Foundation and is a graduate of the University of Manchester and the University of Leicester.

Kristian Thorlund, President & Director, is a data science and artificial intelligence entrepreneur with more than 15 years of experience across health technologies and analytics-focused businesses. He has co-founded five Canadian companies, including two multi-million-dollar exits, and has developed an extensive publication and research record in AI and data analysis. Thorlund also serves as a part-time professor at McMaster University and was previously ranked among the top 1% most cited researchers globally. He is a graduate of the University of Copenhagen and McMaster University and previously a visiting professor at Stanford.

Glenn Sammis, Head of Chemistry, is a chemistry researcher and academic with nearly two decades of experience in chemical sciences and synthesis research. He is a professor at the University of British Columbia and has secured more than $5.5 million in grants during his academic career. In addition to his research work in radical and photochemical processes, Sammis has advised more than 10 private companies on synthesis-related challenges and is a graduate of Stanford University and Harvard University.